Evidence map›Paper›PMID 29687416›Full record

ArticleJournal of endocrinological investigation2018

mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study.

S Mazzeo, R Cervelli, R Elisei, G Tarantini, C Cappelli, E Molinaro, D Galleri, L De Napoli, C Comite, R Cioni and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2020
    Review
  11. Article
  12. Review
  13. Local ablative therapy of oligoprogressive TKI-treated thyroid cancer.Journal of endocrinological investigation · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

S MazzeoDiagnostic and Interventional Radiology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Paradisa, 2, Cisanello Hospital, 56100, Pisa, Italy. salvatore.mazzeo.ph@gmail.com.
R CervelliDiagnostic and Interventional Radiology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Paradisa, 2, Cisanello Hospital, 56100, Pisa, Italy.
R EliseiEndocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
G TarantiniDiagnostic and Interventional Radiology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Paradisa, 2, Cisanello Hospital, 56100, Pisa, Italy.
C CappelliDiagnostic and Interventional Radiology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Paradisa, 2, Cisanello Hospital, 56100, Pisa, Italy.
E MolinaroEndocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
D GalleriGeneral Surgery, Department of Surgical Pathology, Medical, Molecular and Critical Area, University of Pisa, Pisa, Italy.
L De NapoliGeneral Surgery, Department of Surgical Pathology, Medical, Molecular and Critical Area, University of Pisa, Pisa, Italy.
C ComiteDepartment of Anesthesia, University of Pisa, Pisa, Italy.
R CioniDiagnostic and Interventional Radiology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Paradisa, 2, Cisanello Hospital, 56100, Pisa, Italy.
P VittiEndocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
D CaramellaDiagnostic and Interventional Radiology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Paradisa, 2, Cisanello Hospital, 56100, Pisa, Italy.
University of Pisa · ITOspedale Cisanello · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSurgical removal is recommended for recurrent thyroid carcinomas (RTCs) unable to uptake radioiodine and/or not responsive to chemotherapy. However, repeated neck dissection is difficult for surgeons. Thus, radiofrequency ablation (RFA) was proposed for RTCs. The aim of this prospective study is to assess RTC treatment response after RFA, according to well-established criteria.

methodsSixteen lesions in 13 patients were treated by RFA. All patients refused/were excluded from repeated surgery or other conventional therapy. CT and US examinations were performed before RFA to evaluate lesion volume and vascularization. All RFA procedures were performed under US-guidance by an 18-gauge, electrode. Treatment response was evaluated by CT, according to RECIST 1.1 and to mRECIST guidelines; CT examinations were performed during follow-up (6-18 months); the volume of residual vital tumour tissue and the percentage of necrotic tissue were estimated by contrast enhanced CT.

resultsRFA was well tolerated by all patients; in two cases laryngeal nerve paralysis was observed. Mean pre-treatment volume was 4.18 ± 3.53 ml. Vital tumour tissue and percentage of necrosis at 6, 12 and 18 months were 0.18 ± 0.25, 0.11 ± 0.13, 0.29 ± 0.40 ml and 91.9 ± 11.1, 90.4 ± 13.3, 80.8 ± 23.1%. According to RECIST 1.1, target lesion response was classified as complete response (CR) in one case, partial response (PR) in 11/16, stable disease in 4/16 cases. According to mRECIST, 11/16 cases were classified as CR and the remaining 5 as PR.

conclusionRFA is a safe procedure to treat the viable tumour tissue and to reduce the RTC volume; as to the criteria to assess treatment response, mRECIST appears to be more accurate.

Indexed as

Radiofrequency AblationAgedAged, 80 and overCarcinoma, MedullaryCarcinoma, PapillaryFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesThyroid NeoplasmsTreatment OutcomeUltrasonographyAblationNon-vascular interventionsRadiofrequency ablationThyroid cancerUltrasound

Identifiers

PMID29687416
OpenAlexW2802033165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.